Quantitative home-based assessment of Parkinson's symptoms: the SENSE-PARK feasibility and usability study.

Autor: Ferreira JJ; Clinical Pharmacology Unit, Instituto de Medicina Molecular, Lisbon, Portugal. cgcgodinho@gmail.com.; Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Lisbon, Portugal. cgcgodinho@gmail.com.; CNS - Campus Neurológico Sénior, Torres Vedras, Portugal. cgcgodinho@gmail.com., Godinho C; Clinical Pharmacology Unit, Instituto de Medicina Molecular, Lisbon, Portugal. cgcgodinho@gmail.com.; CNS - Campus Neurológico Sénior, Torres Vedras, Portugal. cgcgodinho@gmail.com.; Center for Interdisciplinary Research Egas Moniz (CiiEM), Cooperativa de Ensino Superior Egas Moniz, Monte de Caparica, Caparica, Portugal. cgcgodinho@gmail.com., Santos AT; Clinical Pharmacology Unit, Instituto de Medicina Molecular, Lisbon, Portugal. aa.teresa.ss@gmail.com., Domingos J; Clinical Pharmacology Unit, Instituto de Medicina Molecular, Lisbon, Portugal. domingosjosefa@gmail.com., Abreu D; Clinical Pharmacology Unit, Instituto de Medicina Molecular, Lisbon, Portugal. daideabreu@gmail.com., Lobo R; Clinical Pharmacology Unit, Instituto de Medicina Molecular, Lisbon, Portugal. raquel.jl.lobo@gmail.com., Gonçalves N; Clinical Pharmacology Unit, Instituto de Medicina Molecular, Lisbon, Portugal. nilzakarina@gmail.com., Barra M; Clinical Pharmacology Unit, Instituto de Medicina Molecular, Lisbon, Portugal. marciocbarra@gmail.com., Larsen F; NST-Norwegian Centre for Integrated Care and Telemedicine, University Hospital North Norway, Tromsø, Norway. Frank.Larsen@telemed.no., Fagerbakke Ø; NST-Norwegian Centre for Integrated Care and Telemedicine, University Hospital North Norway, Tromsø, Norway. oyvind.fagerbakke@framhelse.no., Akeren I; NST-Norwegian Centre for Integrated Care and Telemedicine, University Hospital North Norway, Tromsø, Norway. ingvild.akeren@framhelse.no., Wangen H; NST-Norwegian Centre for Integrated Care and Telemedicine, University Hospital North Norway, Tromsø, Norway. Hilde.wangen@framhelse.no., Serrano JA; NST-Norwegian Centre for Integrated Care and Telemedicine, University Hospital North Norway, Tromsø, Norway. jarturserrano@gmail.com.; Department of Clinical Medicine, Faculty of Health Sciences, The Arctic University of Norway, Tromsø, Norway. jarturserrano@gmail.com., Weber P; Hasomed GmbH, Magdeburg, Germany. weber.peter@hasomed.de., Thoms A; Hasomed GmbH, Magdeburg, Germany. andrea.thoms@hasomed.de., Meckler S; HSG-IMIT, Villingen-Schwenningen, Germany. stefan.meckler@hsg-imit.de., Sollinger S; AbilityNet, London, UK. stefan.sollinger@abilitynet.org.uk., van Uem J; Hertie Institute for Clinical Brain Research, Department of Neurodegeneration, Center of Neurology, University of Tuebingen, Tuebingen, Germany. janetvanuem@gmail.com.; DZNE, German Center for Neurodegenerative Diseases, Tübingen, Germany. janetvanuem@gmail.com., Hobert MA; Hertie Institute for Clinical Brain Research, Department of Neurodegeneration, Center of Neurology, University of Tuebingen, Tuebingen, Germany. markus.hobert@med.uni-tuebingen.de.; DZNE, German Center for Neurodegenerative Diseases, Tübingen, Germany. markus.hobert@med.uni-tuebingen.de., Maier KS; Hertie Institute for Clinical Brain Research, Department of Neurodegeneration, Center of Neurology, University of Tuebingen, Tuebingen, Germany. katrin-simone.maier@student.uni-tuebingen.de.; DZNE, German Center for Neurodegenerative Diseases, Tübingen, Germany. katrin-simone.maier@student.uni-tuebingen.de., Matthew H; The Cure Parkinson's Trust, London, UK. helen@cureparkinsons.org.uk., Isaacs T; The Cure Parkinson's Trust, London, UK. tom@cureparkinsons.org.uk., Duffen J; The Cure Parkinson's Trust, London, UK. joy@cureparkinsons.org.uk., Graessner H; Institute for Medical Genetics and Applied Genomics, University of Tübingen, Tuebingen, Germany. holm.graessner@med.uni-tuebingen.de., Maetzler W; Hertie Institute for Clinical Brain Research, Department of Neurodegeneration, Center of Neurology, University of Tuebingen, Tuebingen, Germany. walter.maetzler@uni-tuebingen.de.; DZNE, German Center for Neurodegenerative Diseases, Tübingen, Germany. walter.maetzler@uni-tuebingen.de.
Jazyk: angličtina
Zdroj: BMC neurology [BMC Neurol] 2015 Jun 10; Vol. 15, pp. 89. Date of Electronic Publication: 2015 Jun 10.
DOI: 10.1186/s12883-015-0343-z
Abstrakt: Background: Currently, assessment of symptoms associated with Parkinson's disease is mainly performed in the clinic. However, these assessments have limitations because they provide only a snapshot of the condition.
Methods: The feasibility and usability of an objective, continuous and relatively unobtrusive system (SENSE-PARK System), which consists of wearable sensors (three worn during the day and one worn at night), a smartphone-based App, a balance board and computer software, was tested 24/7 over 12 weeks in a study including 22 PD patients. During the first four weeks of the study, patients did not get feedback about their performance, during the last eight weeks they did. The study included seven clinical visits with standardized interviews, and regular phone contact. The primary outcome was the number of drop-outs during the study. As secondary outcomes, the Post-Study System Usability Questionnaire (PSSUQ), score and information obtained from the standardized interviews were used to evaluate the usability of the system.
Results: All patients completed the study. The participants rated the usability of the SENSE-PARK System with a mean score of 2.67 (±0.49) on the PSSUQ. The interviews revealed that most participants liked using the system and appreciated that it signaled changes in their health condition.
Conclusions: This 12 week controlled study demonstrates that the acceptance level of PD patients using the SENSE-PARK System as a home-based 24/7 assessment is very good. Particular emphasis should be given to a user-friendly design. Motivation to wear such a system can be increased by providing direct feedback about the individual health condition.
Databáze: MEDLINE
Externí odkaz: